Skip to content

Evaluation of the effect of Escitalopram versus placebo trial on changing the neuroticism

Evaluation of the effect of Escitalopram versus placebo trial on changing the neuroticism

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211208053331N1
Enrollment
172
Registered
2022-07-03
Start date
2022-07-23
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroticism or neuroticism. Post-traumatic stress disorder, acute

Interventions

Intervention 1: Intervention group: Subjects aged 24-45 years with nouroticism traits above 24 will be treated with Es citalopram at a dose of 20 mg/day for 4 weeks. Intervention 2: Control group: Pl

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
24 Years to 45 Years

Inclusion criteria

Inclusion criteria: Neuroticism traits based on NEO-60 questionnaire with a score higher than 24 ?Age-range 24-45 years old Obtaining informed consent from the individuals

Exclusion criteria

Exclusion criteria: Pregnancy or intention to conceive Lactation Presence of psychiatric disorder based on GHQ questionnaire with a score above 23 Previous history of SSRI antidepressant intolerance Patients with severe side effects of citalopram Patients with a history of chronic diseases such as brain and heart disease, vascular, seizures People with a history of drug abuse.

Design outcomes

Primary

MeasureTime frame
Flexibility. Timepoint: At the beginning of the study, 2 and 4 weeks after intervention. Method of measurement: Personality Inventory-Revised questionnaire.;Responsibility. Timepoint: At the beginning of the study, 2 and 4 weeks after intervention. Method of measurement: Personality Inventory-Revised questionnaire.;Psychotic. Timepoint: At the beginning of the study, 2 and 4 weeks after intervention. Method of measurement: Personality Inventory-Revised questionnaire.;Extraversion. Timepoint: At the beginning of the study, 2 and 4 weeks after intervention. Method of measurement: Personality Inventory-Revised questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Norouzi

Ahvaz University of Medical Sciences

norouzi-s@sums.ac.ir+98 902 594 3609

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026